Precision NanoSystems, Inc. (PNI), a global leader in technologies and solutions for development of genetic medicines, announced today that it has received a contribution of CAD $25.1 million through the Strategic Innovation Fund (SIF). This contribution will support a CAD $50.2-...

Precision Nanosystems, Inc., a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development’s (ISED) ...

CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology. Precision NanoSystems will lead RNA vaccine formulation development. CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials

Read More

Entos Pharmaceuticals partners with Precision Nanosystems to enable highly scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine and other genetic nanomedicines

Precision NanoSystems (PNI), a global leader in enabling transformative nanomedicines today announced the appointment of Dr. Andrew Geall as the company’s Chief Scientific Officer (CSO).  Dr. Geall has over 20 years’ experience in the development of drug deliv...

The NIH and Moderna have begun phase 1 clinical trials for a vaccine to protect against COVID-19. The vaccine, called mRNA-1273, is an advanced mRNA vaccine that utilizes genetic material to immunize patients. Moderna and the NIH were able to bring mRNA-1273 to clinical trials wi...